263 related articles for article (PubMed ID: 26489937)
1. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis.
Stolk WA; Walker M; Coffeng LE; Basáñez MG; de Vlas SJ
Parasit Vectors; 2015 Oct; 8():552. PubMed ID: 26489937
[TBL] [Abstract][Full Text] [Related]
2. How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control.
Verver S; Walker M; Kim YE; Fobi G; Tekle AH; Zouré HGM; Wanji S; Boakye DA; Kuesel AC; de Vlas SJ; Boussinesq M; Basáñez MG; Stolk WA
Clin Infect Dis; 2018 Jun; 66(suppl_4):S267-S274. PubMed ID: 29860291
[TBL] [Abstract][Full Text] [Related]
3. What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
Hamley JID; Blok DJ; Walker M; Milton P; Hopkins AD; Hamill LC; Downs P; de Vlas SJ; Stolk WA; Basáñez MG
Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):269-280. PubMed ID: 33515042
[TBL] [Abstract][Full Text] [Related]
4. Can ivermectin mass treatments eliminate onchocerciasis in Africa?
Winnen M; Plaisier AP; Alley ES; Nagelkerke NJ; van Oortmarssen G; Boatin BA; Habbema JD
Bull World Health Organ; 2002; 80(5):384-91. PubMed ID: 12077614
[TBL] [Abstract][Full Text] [Related]
5. Reaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa.
Turner HC; Walker M; Churcher TS; Osei-Atweneboana MY; Biritwum NK; Hopkins A; Prichard RK; Basáñez MG
Clin Infect Dis; 2014 Oct; 59(7):923-32. PubMed ID: 24944228
[TBL] [Abstract][Full Text] [Related]
6. Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal.
Walker M; Stolk WA; Dixon MA; Bottomley C; Diawara L; Traoré MO; de Vlas SJ; Basáñez MG
Epidemics; 2017 Mar; 18():4-15. PubMed ID: 28279455
[TBL] [Abstract][Full Text] [Related]
7. Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes.
Dadzie Y; Amazigo UV; Boatin BA; Sékétéli A
Infect Dis Poverty; 2018 Jul; 7(1):63. PubMed ID: 29966535
[TBL] [Abstract][Full Text] [Related]
8. Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment.
Coffeng LE; Stolk WA; Hoerauf A; Habbema D; Bakker R; Hopkins AD; de Vlas SJ
PLoS One; 2014; 9(12):e115886. PubMed ID: 25545677
[TBL] [Abstract][Full Text] [Related]
9. Progress towards onchocerciasis elimination in the participating countries of the African Programme for Onchocerciasis Control: epidemiological evaluation results.
Tekle AH; Zouré HG; Noma M; Boussinesq M; Coffeng LE; Stolk WA; Remme JH
Infect Dis Poverty; 2016 Jun; 5(1):66. PubMed ID: 27349645
[TBL] [Abstract][Full Text] [Related]
10. River Blindness: Mathematical Models for Control and Elimination.
Basáñez MG; Walker M; Turner HC; Coffeng LE; de Vlas SJ; Stolk WA
Adv Parasitol; 2016; 94():247-341. PubMed ID: 27756456
[TBL] [Abstract][Full Text] [Related]
11. Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?
Kura K; Milton P; Hamley JID; Walker M; Bakajika DK; Kanza EM; Opoku NO; Howard H; Nigo MM; Asare S; Olipoh G; Attah SK; Mambandu GL; Kennedy KK; Kataliko K; Mumbere M; Halleux CM; Hopkins A; Kuesel AC; Kinrade S; Basáñez MG
Philos Trans R Soc Lond B Biol Sci; 2023 Oct; 378(1887):20220277. PubMed ID: 37598705
[TBL] [Abstract][Full Text] [Related]
12. Modelling Anti-Ov16 IgG4 Antibody Prevalence as an Indicator for Evaluation and Decision Making in Onchocerciasis Elimination Programmes.
Lont YL; Coffeng LE; de Vlas SJ; Golden A; de Los Santos T; Domingo GJ; Stolk WA
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005314. PubMed ID: 28114304
[TBL] [Abstract][Full Text] [Related]
13. Macrofilaricides and onchocerciasis control, mathematical modelling of the prospects for elimination.
Alley WS; van Oortmarssen GJ; Boatin BA; Nagelkerke NJ; Plaisier AP; Remme JH; Lazdins J; Borsboom GJ; Habbema JD
BMC Public Health; 2001; 1():12. PubMed ID: 11734070
[TBL] [Abstract][Full Text] [Related]
14. Impact of short-term discontinuation of ivermectin-based chemoprevention on onchocerciasis transmission in endemic settings with long history of mass drug administration.
Efon-Ekangouo A; Nana-Djeunga HC; Nzune-Toche N; Dongmo-Yemele R; Bopda J; Ongbassomben V; Sumo L; Geiger A; Nutman TB; Kamgno J
PLoS Negl Trop Dis; 2023 Apr; 17(4):e0011250. PubMed ID: 37058547
[TBL] [Abstract][Full Text] [Related]
15. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections.
Turner HC; Walker M; Churcher TS; Basáñez MG
Parasit Vectors; 2014 May; 7():241. PubMed ID: 24886747
[TBL] [Abstract][Full Text] [Related]
16. African Programme For Onchocerciasis Control 1995-2015: model-estimated health impact and cost.
Coffeng LE; Stolk WA; Zouré HG; Veerman JL; Agblewonu KB; Murdoch ME; Noma M; Fobi G; Richardus JH; Bundy DA; Habbema D; de Vlas SJ; Amazigo UV
PLoS Negl Trop Dis; 2013; 7(1):e2032. PubMed ID: 23383355
[TBL] [Abstract][Full Text] [Related]
17. The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data.
Turner HC; Walker M; Attah SK; Opoku NO; Awadzi K; Kuesel AC; Basáñez MG
Parasit Vectors; 2015 Mar; 8():167. PubMed ID: 25889256
[TBL] [Abstract][Full Text] [Related]
18. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.
Cupp EW; Sauerbrey M; Richards F
Acta Trop; 2011 Sep; 120 Suppl 1():S100-8. PubMed ID: 20801094
[TBL] [Abstract][Full Text] [Related]
19. Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis.
Mutono N; Basáñez MG; James A; Stolk WA; Makori A; Kimani TN; Hollingsworth TD; Vasconcelos A; Dixon MA; de Vlas SJ; Thumbi SM
Lancet Glob Health; 2024 May; 12(5):e771-e782. PubMed ID: 38484745
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of Onchocerciasis Elimination Using a "Test-and-not-treat" Strategy in Loa loa Co-endemic Areas.
Blok DJ; Kamgno J; Pion SD; Nana-Djeunga HC; Niamsi-Emalio Y; Chesnais CB; Mackenzie CD; Klion AD; Fletcher DA; Nutman TB; de Vlas SJ; Boussinesq M; Stolk WA
Clin Infect Dis; 2021 Jun; 72(12):e1047-e1055. PubMed ID: 33289025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
